Boston Scientific (BSX) Beats on Q1 Earnings, Lifts ’18 View
Boston Scientific Corporation BSX posted adjusted earnings per share (EPS) of 33 cents in the first quarter of 2018, up 13.8% from the year-ago quarter. Earnings also surpassed the Zacks Consensus Estimate of 31 cents. Further, adjusted EPS exceeded the company’s guided range of 30-32 cents.
The company reported EPS of 21 cents was in line with the year-ago quarter.
Revenues in Detail
Revenues in the first quarter were up 10.1% year over year on a reported basis and up 6.2% on operational basis (at constant exchange rate or CER) to $2.38 billion. The revenue figure exceeded the Zacks Consensus Estimate of $2.34 billion.
Organic revenue growth in the first quarter (excluding the impact of changes in foreign currency exchange rates and sales from the acquisitions of Symetis SA) was 5.2% year over year.
Geographically, in the first quarter, the company achieved 4.8% operational growth in the United States (same organically), up 10% in Europe, Middle East and Africa region (up 5.7%); up 5.8% in the Asia Pacific region (same), up 9.5% in Latin America and Canada (up 8.6%) and up 17.2% in the emerging markets (up 16.7%).
Boston Scientific currently has three global reportable segments: Cardiovascular, Rhythm and Neuro and MedSurg.
The company generates maximum revenues from Cardiovascular. Sales from its subsegments — Interventional Cardiology and Peripheral Interventions — were $645 million (up 1.3% year over year organically) and $288 million (up 6%), respectively, during the first quarter.
The second largest contributor to Boston Scientific’s top line was the Rhythm and Neuro business, comprising Cardiac Rhythm Management (CRM), Electrophysiology and Neuromodulation. CRM reflected a 2.4% year-over-year increase in organic sales to $493 million in the reported quarter.
Electrophysiology sales went up 11.5% year over year organically to $75 million.
Neuromodulation sales rose 17.2% year over year organically to $169 million.
Other segments like Endoscopy and Urology and Pelvic Health (under the MedSurg broader group) recorded sales of $418 million (up 6.2% organically) and $293 million (up 9.2%) respectively.
Gross margin in the first quarter expanded 190 basis points (bps) year over year to 71.8% on 3.4% rise in cost of products sold. Adjusted operating margin improved 240 bps to 23.9% in the reported quarter. During the quarter, selling, general and administrative expenses went up 8.3% to $860 million while research and development expenses rose 11.1% to $261 million. Royalty expenses inched up 5.9% to $18 million in the quarter.
Boston Scientific has provided an updated guidance for 2018. The company projects current-year revenues in the range of $9.750-$9.900 billion, compared with the previous $9.650-$9.800 billion (annualized growth of 8-10% on a reported basis and 5-7% on an organic basis (at CER and including contribution of approximately 40 bps from Symetis). The Zacks Consensus Estimate for current-year revenues is pegged at $9.74 billion, below the guided range.
Adjusted EPS guidance for 2018 is estimated in the range of $1.37-$1.41 as compared with the previous range of $1.35-$1.39. The Zacks Consensus Estimate of $1.37 is pegged at the low end of the guided band.
The company also provided its second-quarter 2018 financial outlook. Adjusted EPS are expected in the band of 33-35 cents on revenues of $2.450-$2.500 billion. The consensus mark for EPS stands at 35 cents while the same for revenues is at $2.44 billion.
Boston Scientific posted an impressive first quarter. Growth across all business lines and geographies was promising as well. The 2018 view is also paints a bright picture for the near term.
Boston Scientific is leaving no stone unturned to strengthen its core businesses and invest in new technologies as well as global markets, which have accounted for the uptick in sales across all geographies in the first quarter.
We are also optimistic about the company achieving clinical milestones for products like Ranger Drug Coated Balloon and WATCHMAN Left Atrial Appendage Closure (LAAC) Device.
During the quarter, Boston Scientific announced an agreement to buy Minnesota-based NxThera for a deal value of up to $406 million. Privately-held NxThera is the developer and marketer of the Rezum system in the United States and Europe.
Zacks Rank & Key Picks
Boston Scientific has a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Abaxis, Inc. ABAX, Bio-Rad Laboratories, Inc. BIO and ResMed Inc. RMD). While Abaxis and Bio-Rad sport a Zacks Rank #1 (Strong Buy), ResMed carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Abaxis is expected to release fourth-quarter fiscal 2018 results on Apr 26. The Zacks Consensus Estimate for adjusted EPS is 32 cents and for revenues is $67 million.
Bio-Rad is expected to report first-quarter 2018 results on May 3. The Zacks Consensus Estimate for adjusted EPS is 90 cents and for revenues is $529.5 million.
ResMed is slated to release third-quarter fiscal 2018 results on Apr 26. The Zacks Consensus Estimate for adjusted EPS is 83 cents and for revenues is $564.9 million.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
ResMed Inc. (RMD): Free Stock Analysis Report
Abaxis,Inc. (ABAX): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research